Immuron announces positive results support travelan® progress to phase 3 clinical trials in the us

Highlights: immuron proceeding to phase 3 registration strategy with the fda travelan® topline clinical trial results demonstrate protective efficacy with single daily dose 36.4% protective efficacy against enterotoxigenic escherichia coli (etec) induced moderate to severe diarrhea was observed in the travelan® group compared to the placebo group (primary endpoint) 66.7% protective efficacy against etec induced severe diarrhea was observed in the travelan® group compared to the placebo group (secondary endpoint) 83.3% statistically significant reduction in the number of subjects in the travelan® group requiring early antibiotic treatment post challenge compared to the placebo (secondary endpoint) 100% of the subjects requiring iv fluids post challenge were in the placebo (secondary endpoint) 55.6% reduction in the number of subjects experiencing adverse events associated with the etec challenge observed in the travelan® group compared to the placebo group (secondary endpoint) phase 2 clinical study data supports the excellent safety and tolerability profile of travelan® melbourne, australia, march 07, 2024 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company is pleased to announce the interim topline results confirming that a single daily dose of travelan® is effective in prevention of moderate to severe diarrhea following challenge with enterotoxigenic escherichia coli (etec). immuron was awarded au $4.8 (usd $3.43) million funding by the u.s. department of defense (asx announcement 12 january 2022) to perform a randomized double-blind placebo-controlled phase 2 controlled human infection model (chim) study to assist with evaluating a dosing regimen that is most suited to deployed us troops visiting developing countries.
IMRN Ratings Summary
IMRN Quant Ranking